Medicus Pharma Regains Nasdaq Bid Price Compliance Days After Delisting Determination
MDCX is trading near its 52-week low of $2.5 (0.0% above the low).
Summary
Nasdaq issued a delisting determination on October 20, 2026, then closed the matter on October 23 after the post-reverse-split share price held above $1.00 for ten business days. The company remains ineligible for a second compliance period because it falls short of the $5 million stockholders' equity requirement.
Key Events · Legal and Risk Events · MDCX
-
Delisting Determination Issued, Then Cured
Nasdaq issued a delisting determination letter on October 20, 2026 after the shares failed to regain the $1.00 minimum bid by the October 19, 2026 deadline; a Compliance Notice dated October 23, 2026 confirmed compliance and closed the matter.
-
Ten-Day Bid Price Test Passed
Nasdaq found the closing bid price was at $1.00 or greater for the ten consecutive business days from October 12, 2026 to October 23, 2026, following the 50-to-1 reverse split executed October 12, 2026.
-
No Second Compliance Window Available
Nasdaq denied a second 180-day period because the company does not meet the $5 million stockholders' equity requirement under the Nasdaq Capital Market initial listing criteria.
-
Compliance Not Guaranteed Going Forward
The filing states there can be no assurance the company will maintain compliance with the minimum bid price or Nasdaq's other continued listing requirements.
Analysis · MDCX · Life Sciences
Medicus briefly faced removal from Nasdaq: on October 20, 2026 the listing staff issued a delisting determination because the shares had not held $1.00 by the October 19 deadline, and the company was denied a second 180-day window since it does not meet the $5 million stockholders' equity test. The 50-to-1 reverse split executed October 12 did its job — Nasdaq confirmed on October 23 that the closing bid held at $1.00 or more for ten straight business days, so the matter is closed. The listing risk is off the table for now, but the underlying problem is unchanged: the company still fails the equity standard, so any future dip below $1.00 restarts the clock with no second grace period available.
How filings like this one have moved
In the 30 days to Oct 23, 2026, 36.8% of the 1025 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.77%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, MDCX was trading at $2.50 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $4.6M. The 52-week trading range was $2.50 to $139.00. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.